Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Author [ Title] Type Year Filters: Author is Karagiannis, Asterios [Clear All Filters]
Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?.
Curr Vasc Pharmacol. 8(5), 720-30.
(2010). Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension..
Clin Exp Hypertens. 28(7), 603-9.
(2006).
(2017).
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Metabolism. 71, 17 - 32.
(2017). Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult..
Ren Fail. 30(3), 331-4.
(2008).
(2005). Triglycerides and vascular risk: insights from epidemiological data and interventional studies..
Curr Drug Targets. 10(4), 320-7.
(2009). Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy..
Expert Rev Cardiovasc Ther. 13(9), 1059-66.
(2015). Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand's disease with administration of octreotide LAR and propranolol..
Hormones (Athens). 3(1), 65-7.
(2004). Treating heart failure with preserved ejection fraction: statins could make the difference..
Angiology. 65(4), 328-9.
(2014). Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?.
Cardiology. 131(3), 186-8.
(2015). To switch (statins) or not to switch? That is the question..
Expert Opin Pharmacother. 11(18), 2943-6.
(2010). Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk..
Angiology. 63(1), 9-11.
(2012). Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?.
Dig Liver Dis.
(2019). Is there any association between adiponectin gene polymorphisms and cardiovascular disease?.
Angiology. 64(4), 253-6.
(2013). Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data..
Angiology. 65(6), 543-50.
(2014). Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study..
Open Cardiovasc Med J. 10, 64-8.
(2016). Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?.
Arch Med Sci. 7(6), 1067-75.
(2011). Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?.
Open Cardiovasc Med J. 6, 28-32.
(2012). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005). Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?.
Curr Vasc Pharmacol. 14(1), 88-97.
(2016).
(2019). Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?.
J Hypertens. 36(3), 701.
(2018). Subclinical Cushing's syndrome and cardiovascular disease..
Lancet Diabetes Endocrinol. 2(5), 361.
(2014).